Ken Griffin Vaxcyte, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 29,900 shares of PCVX stock, worth $2.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,900

Previous 20,100 48.76%

Holding current value

$2.57 Million

Previous $1.52 Million 124.98%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $413,740 - $687,143	5,867 New	5,867 $669,000
Q1 2024 May 15, 2024	BUY	$59.79 - $81.05 $7,115 - $9,644	119 New	119 $8,000
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $1.02 Million - $1.17 Million	22,106 New	22,106 $1.13 Million
Q1 2023 May 15, 2023	BUY	$36.27 - $47.2 $81,680 - $106,294	2,252 Added 0.26%	854,110 $32 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $390,834 - $910,618	18,991 Added 2.28%	851,858 $40.8 Million
Q3 2022 Nov 14, 2022	SELL	$21.69 - $28.53 $3.69 Million - $4.85 Million	-170,119 Reduced 16.96%	832,867 $20 Million
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $5.04 Million - $7.58 Million	285,031 Added 39.7%	1,002,986 $21.8 Million
Q1 2022 May 16, 2022	BUY	$17.46 - $26.36 $11.1 Million - $16.7 Million	635,105 Added 766.57%	717,955 $17.3 Million
Q4 2021 Feb 14, 2022	BUY	$19.32 - $26.45 $717,081 - $981,718	37,116 Added 81.16%	82,850 $1.97 Million
Q3 2021 Nov 15, 2021	SELL	$20.26 - $26.97 $977,808 - $1.3 Million	-48,263 Reduced 51.35%	45,734 $1.16 Million
Q2 2021 Aug 16, 2021	SELL	$16.45 - $24.06 $277,018 - $405,170	-16,840 Reduced 15.19%	93,997 $2.12 Million
Q1 2021 May 17, 2021	SELL	$18.66 - $29.16 $1.57 Million - $2.45 Million	-83,974 Reduced 43.11%	110,837 $2.19 Million
Q4 2020 Feb 16, 2021	BUY	$26.57 - $51.74 $3.78 Million - $7.36 Million	142,252 Added 270.65%	194,811 $5.18 Million
Q3 2020 Nov 16, 2020	SELL	$26.5 - $55.4 $13.2 Million - $27.5 Million	-497,192 Reduced 90.44%	52,559 $2.6 Million
Q2 2020 Aug 14, 2020	BUY	$26.15 - $35.45 $14.4 Million - $19.5 Million	549,751 New	549,751 $17.4 Million

Others Institutions Holding PCVX

# of Institutions

352

Shares Held

122M

Call Options Held

775K

Put Options Held

433K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.1B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account